Asthma affects approximately 300 million individuals worldwide. Medications comprise a substantial portion of asthma expenditures. Despite the availability of three primary therapeutic classes of medications, there are a significant number of nonresponders to therapy. Available data, as well as previous pharmacogenetic studies, suggest that genetics may contribute as much as 60-80% to the interindividual variability in treatment response. In this methodologic review, after providing a broad overview of the asthma pharmacogenetics literature to date, we describe the application of a novel family-based screening algorithm to the analysis of pharmacogenetic data and highlight our approach to identifying and verifying loci influencing asthma treatment response. This approach seeks to address issues related to multiple comparisons, statistical power, population stratification, and failure to replicate from which previous population-based or case-control pharmacogenetic association studies may suffer. Identification of such replicable loci is the next step towards the goal of 'individualized therapy' for asthma. The Pharmacogenomics Journal (2006) 6, 311-326. doi:10.1038/sj.tpj.6500387; published online 25 April 2006
Introduction
The goal of this review is to give a comprehensive assessment of asthma pharmacogenetics and highlight the scientific approach being taken by the pharmacogenetics of asthma treatment (PHAT) research group (http:// www.pharmgat.org/) to this research area. Our approach strives to address many of the potential problems inherent in genetic association studies, including those related to multiple comparisons, lack of statistical power, population stratification, and failure to replicate. Moreover, our group of collaborative investigators is well positioned to investigate the molecular biology and functional genomics of identified candidate gene associations. In this review, we will cover some aspects of asthma health care, pathobiology, and review the available pharmacogenetics literature on the important types and pathways of asthma medications: b-agonists, leukotriene (LT) antagonists, methylxanthines, and corticosteroids. We will then present details of our research approach to finding replicated pharmacogenetic associations and suggest what the future may hold for this research area.
Pharmacogenetics -definition and rationale
Pharmacogenetics is the study of the role of genetic determinants in the variable, interindividual response to medications. Numerous examples of heritable differences in pharmacokinetics (drug distribution and metabolism) in individuals resulting in varied clinical response to medications have been described. 1 Other mechanisms underlying the genetic response to drugs includes alterations in pharmacodynamics (changes in the drug target), idiosyncratic associations (unintended side effects in predisposed individuals), and genetic predisposition to the disease in which the treatment is to be instituted 2, 3 Overall, it is estimated that genetics can account for 20-95% of variability in drug disposition and effects. 2 In corticosteroid therapy, a number of family and twin studies have demonstrated consistent evidence that endogenous levels of glucocorticoids (GC), usually measured as plasma cortisol levels at certain times of the day, are heritable. [4] [5] [6] [7] [8] We have generated similar heritability data for bronchodilator response in a Chinese population. 9 As the initial sequence of the human genome was published, 10, 11 the concept that genetic variation will allow prediction of treatment response has been seen as an important and achievable goal. [12] [13] [14] Further, the food and drug administration has drafted guidelines requiring drug development companies to submit pharmacogenetic information when reporting clinical trial results. Ideally, pharmacogenetics will allow for 'individualized therapy' that is tailored to an individual's genetic make-up to maximize the potential for therapeutic benefit, while minimizing the risk of adverse effects. The potential for cost savings and for decreasing morbidity and mortality is immense because the target therapies are so widely used.
Asthma -overview and rationale
The burden of asthma Asthma is a complex disease affecting over 300 million individuals in the developed world. 15 Of all asthma cases, 90%, including asthma in adults, has its origins in childhood. Of concern are the increases in asthma prevalence 16 and hospitalization rates. 17 Between 1980 and 1994, the selfreported prevalence of asthma in the USA increased from 30.7 to 53.8 per 1000, an increase of 75%. 16 This increase has been accompanied by a similar increase in health care utilization and mortality over the same time period. 16 An estimated 12.6 billion dollars were spent on the diagnosis and management of asthma in the US in 1998, of which 58% were direct medical expenditures (DMEs). 18 Medication costs are currently the largest component of DMEs. Despite the availability of several classes of therapeutic agents for asthma, it has been estimated that as many as one-half of asthmatic patients do not respond to treatment with b 2 -agonists, LT antagonists, or inhaled corticosteroids. 3, 19, 20 As a whole, adverse drug reactions are estimated to cost the US $100 billion and over 100 000 deaths a year. 21 Asthma therapy has been associated with adverse drug reactions, including serious and potentially fatal complications. [22] [23] [24] Asthma: definition, clinical features, pathobiology Asthma is a clinical syndrome of unknown etiology characterized by reversible episodes of airflow obstruction, airway hyperresponsiveness, and a chronic inflammatory process of the airways of which mast cells, eosinophils, T lymphocytes, epithelial cells, and airway smooth muscle cells play a prominent role. 25 Figure 1 shows important pathobiologic features of asthma. Genetics in combination with early life environment modulate the development of CD4/lymphocytes towards a Th2 immunophenotype. These lymphocytes then produce cytokines, such as interleukin (IL)-3, IL-4, IL-5, IL-13, and granulocyte-macrophage colony-stimulating factor (GM-CSF) and thereby promote the synthesis of IgE, an important allergic effector molecule, resulting in an inflammatory airway milieu. Chemokines, such as eotaxin, RANTES, and IL-8 produced by epithelial and inflammatory cells, serve to amplify and perpetuate the inflammatory events. Several bronchoactive mediators, such as histamine, LT, and neuropeptides are released into the airways and precipitate an asthma attack by causing airway smooth muscle constriction, mucus secretion, and edema. Over time there is smooth muscle growth and the deposition of subepithelial connective tissue, a process referred to as airway remodeling. This basic asthma pathobiology is important for asthma pharmacogenetics because many genes associated with an altered treatment response are also associated with asthma or its intermediate phenotypes.
Clinically, asthmatics have difficulty exhaling air because of an increase in airway resistance that is a consequence of smooth muscle contraction, inflammation and remodeling ( Figure 1) . In clinical trials, the degree of resistance and physiological impairment is quantitated most commonly by the forced vital capacity in 1 s (FEV 1 ) (Figure 2 ). Forced vital capacity in 1 s is the volume of air a person can 'blow out' in one second and is very useful as a measurement of lung function because it is easily obtained, reproducible, and correlated with asthma severity and therapeutic responses. 26 Another commonly used measurement of the physiological impairment in asthmatics is the peak expiratory flow rate (PEFR). Peak expiratory flow rate is defined as the maximal flow rate achieved during forced exhalation. 27 During an asthma attack, patients experience shortness of breath, cough, and/or wheezing. Between attacks, patients Figure 1 Asthma pathobiology. Asthma is an inflammatory disorder of the airways influenced by multiple early life and genetic factors. The inflammatory response, as well as smooth muscle constriction, lead to airway narrowing and symptoms.
B r o n c h o c o n s t r ic t io n
Overview of the pharmacogenetics of asthma treatment ST Weiss et al may be asymptomatic or they may have chronic symptoms of breathlessness with mild-to-moderate exertion or episodes of nocturnal awakening due to airway narrowing at night. In clinical drug trials, these asthma symptoms are commonly graded and recorded by the patient to give an index of the symptomatic response to asthma treatment. 28 Other potentially useful indices of the effects of asthma treatment are measures of healthcare utilization including doctor visits, urgent care emergency room visits, and hospitalizations. Changes in FEV 1 , PEFR, symptom scores, and healthcare utilization that occur during the course of therapy are important outcome indicators that we will refer to throughout this review.
Asthma therapy
Standard guidelines for the diagnosis and management of asthma have been published. 29 The two main types of asthma drugs are the so-called reliever drugs that target the acute bronchconstriction and the so-called controller drugs that are used to reduce the severity of airway inflammation and the severity and frequency of obstruction. 29 The main reliever drugs are rapid-acting b 2 -agonists (e.g., albuterol, metaproterenol, pirbuterol, and levalbuterol), which relax the bronchial smooth muscle by activating b 2 -adrenergic receptors (b 2 AR). This is the treatment of choice for very mild asthma. For moderate and severe persistent asthma, the reliever treatment is usually combined with controller treatment. The two commonly used classes of controller agents are the inhaled GC and the leukotriene receptor antagonists (LTRA). Inhaled GC (e.g., budesonide, beclomethasone, flunisolide, and fluticasone) and LTRAs (e.g. montelukast and zafirlukast) modify the inflammatory microenvironment of the airway to reduce airway obstruction and hyperresponsiveness. This review will focus on b 2 -agonists and GC because they are the most effective and commonly used asthma drugs and we have outstanding clinical trials data for these pathways although available data on LT and theophylline will be mentioned.
There is large interindividual variation in the treatment response to asthma medications. 19, 30 For example, in a study by Malmstrom et al. 31 comparing the efficacy of the inhaled steroid beclomethasone (200 mg bid) with the LT antagonist montelukast (10 mg/qd), it is clear that both drugs are effective over a 12 week course of treatment with a mean increase in FEV 1 of 13.1% for the beclomethasone group and 7.4% for the montelukast group (Figure 3a) . However, when these same data are viewed from a different perspective, focusing on the number of individuals as a function of percent change in FEV 1 from baseline, it is clear that many patients had little response (Figure 3b ). In fact, 22% of patients appear to have had an adverse response to treatment with a decline in FEV 1 at 12 weeks compared with baseline. The mean therapeutic improvement in FEV 1 for all patients is driven by a dramatic increase in FEV 1 in a minority of trial subjects. In a similar study, 38% of patients randomized to inhaled budesonide or fluticasone demonstrated improvements in FEV 1 of under 5% over the course of 24 weeks. 30 A unique subset of up to 25% of the nonresponders can be classified as having GC-resistant asthma. 32 These patients are nonresponsive to even high doses of oral steroids. Furthermore, a careful analysis of these studies indicates that individuals responsive to one class of asthma drug may not necessarily be the individuals responsive to a different class of asthma drug. Despite these studies, there is no universally accepted definition of a steroid (or b 2 -agonist) nonresponder. These types of data illustrating variable drug efficacy are not limited to asthma drug trials but can be found for almost all classes of drugs.
The degree to which this interindividual variability is genetic remains uncertain and probably differs with each class of drug. Moreover, interindividual variability may depend on the particular preparation within a class of asthma drug. Calculations of the repeatability (r) of the treatment response for all three classes of asthma drugs, defined as the fraction of the total population variance that results from within individual differences, show values for r between 60 and 80% indicating the upper limit of the genetic component and suggesting that a substantial fraction of the variance of the treatment response could be genetic. 19 In support of these data, several genetic variants and haplotypes have recently been discovered in genes that play a role in the action or metabolism of asthma drugs and are associated with altered therapeutic responses. These examples are discussed below. It is likely that many, as yet undiscovered, polymorphisms exist, given the many gene products involved in the pharmacodynamic and pharmacokinetic pathways of asthma drugs. The ultimate goal of asthma pharmacogenetics is to identify this information and use it to tailor an individual's therapeutic regimen in order to maximize efficacy and minimize side effects.
Asthma pharmacogenetics to date
To date, genetic variants in multiple genes have been associated with altered therapeutic response to four classes of asthma drugs. Examples of asthma pharmacogenetics that will be discussed include the b 2 AR, 5-lipoxygenase (ALOX5), leukotriene C 4 synthase (LTC4S), corticotropin releasing factor receptor type 1 (CRHR1) and cytochrome p450 1A2 (CYP1A2) genes. Our laboratories discovered three of these examples; each has been replicated in at least one other clinical drug trial. In the case of the ALOX5 polymorphisms, these genetic variants have been discovered to be important in the context of atherosclerosis as well as asthma. [33] [34] [35] Despite progress in the discovery of asthma pharmacogenetic loci, to date no single variant interrogated has been found to explain more than a small percentage (o10%) of the total phenotypic variance of treatment response that is characteristic of any asthma drug. 19 Part of the reason is that the exact location of the functional variants remains unclear for each of these associations. The molecular mechanisms of their action are also unclear and appear to be complex and multifaceted. 36 It is also highly likely that sequence variants in other genes contribute significantly to the heterogeneity of therapeutic response. Nevertheless, progress has been made and studies are underway to investigate the potential to prospectively determine response to drugs in asthmatics based upon genetic testing. 43 Although the PHAT research focus is on b 2 -agonists and GC, we will review examples of asthma pharmacogenetics for each of four therapeutic pathways for completeness. b 2 -adrenergic receptor polymorphisms and response to b-agonists b 2 -Adrenergic receptor agonists (b 2 -agonists) are the most commonly used class of medication in the treatment of asthma worldwide. 36 A b 2 -agonist inhaler is discharged around the world 19 times a second! b 2 -agonists produce bronchodilitation (increase FEV 1 ) in asthmatics by binding to and directly simulating b 2 ARs on airway smooth muscle cells. b 2 ARs are cell surface receptors (GPCR) that signal to the interior of the cell by multiple mechanisms. In brief, agonists binding to the receptor result in the activation of adenylyl cyclase via stimulatory G proteins (Gs). This leads to an increase in cAMP and activation of protein kinase A (PKA). Protein kinase A phosphorylates several target proteins, decreases intracellular Ca 2 þ , and leads to smooth muscle relaxation. Once b 2 ARs are activated by b 2 -agonists a complex process of tachyphylaxis or 'desensitization' begins. Desensitization functions to attenuate the effects of b 2 -agonists and is mediated by both short-term (e.g. uncoupling of receptor) and long-term mechanisms (e.g., downregulation of receptor expression). The intricacies of this pathway as it related to this proposal are discussed in detail below. A diagram of this pharmacological pathway is shown in (Figure 4 ) and may be viewed on the PharmGKB website (http://www.pharmgkb.org/index.jsp). This diagram accentuates the fact that multiple genes in addition to b 2 AR likely interact in the response to this class of medications.
The b 2 AR is highly polymorphic with over 55 singlenucleotide polymorphisms (SNPs) (B1 every 300 bp) recorded in public databases (http://snpper.chip.org). Two common nonsynonymous SNPs, rs1042713, and rs1042714, have been the most extensively studied. rs1042713 (A/G, 0.44 avg. het.) results in Arg vs Gly at position 16 and rs1042714 (C/G, 0.49 avg. het.) results in Gln vs Glu at position 27. Over the last decade nonsynonymous coding SNPs of the human b 2 AR were identified 37 and characterized in cells by us. [38] [39] [40] [41] Arg or Gly can be found at amino-acid 16, whereas Gln or Glu can be found at position 27. A rare polymorphism Thr164-Ile (5% heterozygous frequency) has also been detected. In transfected cells, Arg16, Gly16, Gln27, and Glu27 b 2 AR (in all possible haplotypic combinations) appeared to have the same agonist binding affinities and coupling to adenylyl cyclase 39 However, agonistpromoted downregulation of receptor number was greatest for Gly16/Gln27 and Gly16/Glu27, compared to Arg16/ Gln27. 39 Interestingly, Arg16/Glu27 failed to downregulate, but this diplotype is very rare in the human population. Subsequent studies in human airway smooth muscle cells expressing the various 16/27 SNPs gave similar results. 41 However, when other end points were utilized the phenotypes were not always as would have been predicted from the transfected cell data. 42, 43 The rare Ile164 b 2 AR has decreased agonist affinity, depressed coupling to adenylyl cyclase, and a decreased duration of action (by B50%) in response to the long-acting b 2 -agonist salmeterol. 38, 40 This functional work on the b 2 AR needs to be expanded to include the promotor and 3' UTR variants newly identified.
Clinical studies have not revealed an association between these SNPs and asthma per se, but a myriad of subphenotypes have been reported to be associated with one or both of these variants. In terms of pharmacogenetics, several studies have reached similar conclusions regarding associations between position 16 SNPs and the response to chronic (regularly scheduled) b 2 -agonist albuterol. These association studies represent the first successful efforts in asthma pharmacogenetics to take data from a retrospective association study and apply it prospectively. Such prospective studies will comprise an important component of future research in this field. Israel et al. 44 reported on the changes in PEFR during albuterol therapy in patients with mild asthma stratified by b 2 AR genotype. Patients with Arg/Arg (i.e., homozygous for Arg16) treated with regularly scheduled albuterol had a slow decline in AM PEFR, which continued even during the washout phase. Neither Gly homozygous individuals or Arg homozygotes on as needed (PRN) albuterol showed no such decline. In another study of similar design, except that prospective enrollment was by homozygous position 16 genotype (BARGE), we noted analogous changes in PEFR, although there were some fundamental difference. 45 In this study, Arg/Arg individuals showed no significant decline in lung function while on regular albuterol, but did display a decrease during washout. Gly/Gly patients on regular albuterol showed improved function and no decrement during washout. 44, 45 These two studies both point to homozygosity at Arg16 being associated with an unsatisfactory response to albuterol. However, the clinical relevance of these findings remains uncertain, since the genotype-attributable treatment difference (the effect of treatment in Arg/Arg patients minus that observed in Gly/Gly patients) was only À24 l/min, which is quite modest. Moreover, since chronic administration of b-agonists on a regularly scheduled basis is not part of recommended treatment guidelines, the clinical applicability of these findings is also uncertain. In another study of mild-moderate asthmatics, 46 exacerbations were significantly greater for Arg/Arg16 individuals compared to heterozygotes or Gly/Gly patients, and indeed were even greater than Arg/Arg patients on placebo. The PEFR trended towards showing a decrease over time for Arg/Arg patients, but this did not reach statistical significance.
The acute bronchodilatory response to albuterol has not been associated with position 16 in any of the above studies. However, certain extended b 2 AR haplotypes appear to confer a differential response. In one study, we identified 13 SNPs (from the promoter forward through the coding region but not including the 3 0 UTR) organized into 12 haplotypes. 47 The change in percent predicted FEV 1 was related to b 2 AR haplotype pair (P ¼ 0.007 by ANCOVA), but not any of the individual SNPs. Of the homozygous haplotype pairs, patients with haplotype 4/4 had the poorest response compared with those with haplotype 2/2. In transfected cells, haplotype 4 had lower mRNA and protein expression compared with haplotype 2. 47 A more recent study by our group utilized restricted b 2 AR genotyping of patients and their parents in the Childhood Asthma Management Program (CAMP). Here, the most intriguing finding was an association between a synonymous SNP at nucleotide position þ 523 in the 3 0 end of the coding region and bronchodilator response. These findings suggest that additional variants, likely in the 3 0 UTR, are in linkage-disequilibrium with þ 523 and may represent the causal polymorphisms for bronchodilator response. As a result of these findings, deep resequencing of the b 2 AR gene has occurred. Indeed, several novel variants, both 5 0 and 3 0 of the gene have now been described. 48 Of interest, a repeat region consisting of a variable number [9] [10] [11] [12] [13] [14] of 'C' alleles at position 1269 has now been identified. Moreover, this poly-C track also contains additional SNP variation, adding to the complexity of the region. By imputing haplotypic substructure, it is clear that the poly-C region subdivides the aforementioned haplotypes further. Moreover, preliminary association studies of these subdivided haplotypes suggests that this region may influence both lung function and bronchodilator response. Confirmatory studies are underway.
Taken together, some aspects of b 2 -agonist pharmacogenetics have been ascertained, but predictability remains low. This lack of predictability is due to an incomplete understanding of the haplotypic structure of the gene and the need to identify and characterize additional functional variants. Even with this information explained phenotypic variation is low. Therefore, genetic variants in other genes in the pathway are likely to be important determinants of b 2 -agonist response and need to be characterized (Figure 4 ).
5-lipoxygenase and leukotriene C 4 synthase polymorphisms and response to leukotriene antagonist
The LT are a family of lipoxygenated eicosatetraenoic acids derived from arachidonic acid and produced in the airways of asthmatics that are potent bronchoconstrictors. Of the many enzymes involved in the formation of the LT, polymorphisms in two, ALOX5 and LTC4S have been associated with altered response to LT inhibitors. 5-lipoxygenase catalyzes the conversion of arachidonic acid to LTA4, which is a rate limiting step involved in the synthesis of all LT. 49 In 221 patients with asthma who received either high-dose ABT-761, an ALOX5 inhibitor similar to zileuton, (n ¼ 114) or placebo (n ¼ 107) treatment, we found that approximately 6% of asthmatic patients had no wild-type allele at the ALOX5 promoter locus and had a diminished response to ABT-761 treatment. 50 These findings were consistent with the hypothesis that repeats of the -GGGCGG-sequence other than the wild type are associated with decreased gene transcription and ALOX5 product production. This has recently been confirmed in cells obtained from patients with asthma. 51 Another enzyme of the LT pathway, LTC4S, is responsible for the adduction of glutathione at the C-6 position of the arachidonic-acid backbone to form LTC4, a potent bronchoconstrictor. There is a known SNP in the LTC4S promoter, A-444C, with a C allele frequency of 0.19 in normal subjects and of 0.27 in patients with severe asthma. 52 The À444C allele creates an activator protein-2 binding sequence that appears to be functional, 52 suggesting that the À444C variant is associated with enhanced cysteinyl LT production. Sampson et al. 53 found that, among asthmatic subjects treated with zafirlukast (20 mg bid), those homozygous for the A allele (n ¼ 10) at the À444 locus had a lower FEV 1 response than those with the C/C or C/A (n ¼ 13) genotype.
Given the previous associations, we have recently collaborated to perform genotyping on 28 SNPs in five LT pathway genes in subjects participating in a clinical trail comparing the efficacy of montelukast vs low-dose theophylline vs placebo as add on therapy in mild-moderate asthma. 54 DNA was obtained in 248 participants and the primary analysis was performed on 61 Caucasians taking montelukast. Outcomes assessed included change in FEV 1 and presence of exacerbations over 1, 3, and 6 months of time. At 6 months, two SNPs were associated with change in FEV 1 , one in the MRP1 gene (rs119774) and the second in ALOX5 (rs2115819). Of potentially greater interest, variants from three genes were associated with risk of exacerbations. Variation in one LTA4H SNP (rs2660845) was associated with a fourfold increase in the risk of at least one exacerbation over the 6 month follow-up, whereas variation in the previously described ALOX5 promoter repeat and the the LTC4S A-444C SNP was associated with a 73% and a 76% reduction in exacerbations, respectively. Although these findings require replication, they provide evidence of multiple LT pathway pharmacogenetic loci in modulating the therapeutic response to these agents.
CYP1A2 polymorphisms and theophylline metabolism
Theophylline, and related methylxanthine derivatives, have weak bronchodilator and anti-inflammatory effects and are considered second line drugs for asthma. 29 Dose-related toxicities, such as tachycardia, headache, nausea, and seizures are major problems that have limited their use. Serum levels must be monitored closely because of a narrow therapeutic window and a plethora of drug interactions 29 may have anti-inflammatory effects, however, that may not necessitate monitoring. 55 Obase et al. 56 have recently described a common promoter polymorphism in the CYP1A2 gene that is associated with altered clearance of theophylline. Specifically, the A allele of a G/A SNP at position À2964 was associated with decreased clearance (increased serum levels) in a group of 75 Japanese asthmatics. Although these findings need to be replicated, they are biologically plausible because CYP1A2 is known to degrade theophylline to 1,3-dimethyl uric acid before excretion in the urine and poor metabolizers of theophylline are known to exist. If true, this association is the first example of an asthma pharmacogenetic response that is caused by a polymorphism in the pharmacokinetic pathway of a drug.
Corticotropin releasing factor receptor type 1 polymorphisms and response to inhaled glucocorticoids Glucocorticoids are the most potent and commonly prescribed anti-inflammatory agents for the treatment of asthma. [57] [58] [59] Glucocorticoids bind to the glucocorticoid receptor (GR) and function as transcription factors that may activate or repress the expression of many genes. In general, GCs activate anti-inflammatory genes and repress the expression of proinflammatory genes. 60 Treatment of asthmatics with GCs attenuates airway inflammation and hyperresponsiveness by inhibiting inflammatory cell recruitment and the production of proinflammatory cytokines. The majority of asthmatics respond to inhaled GC therapy with a reduction in the numbers of activated eosinophils, mast cells, and T lymphocytes and a decrease in the concentration of cytokines/chemokines in the airways (Table 1) lists some of the many effects of GCs on the airways of asthmatics.
Although inhaled corticosteroids are very effective in those asthmatics who respond, many fail to respond ( Figure  3b ) and the potential for side effects in those receiving higher doses can be significant. 61 These side effects can include growth retardation in children, 62 adrenal suppression 63,64 bone demineralization, 65 skin changes, 66 and cataract formation. 67 The precise reason for GC resistance is unknown. Multiple theories exist and focus on abnormalities in cellular immune response, GC signal transduction, receptor gene conformation, and receptor isoform b-expression 68-70 CRHR1 was chosen as a candidate gene because it is a major regulator of GC synthesis, it has been implicated in the pathogenesis of inflammatory diseases, and it is located on chromosome 17q21-22, a region linked to asthma in some genomewide screens. 71 It is also located in a genomic region that is orthologous with a region of the mouse genome on chromosome 11 that has been linked to AHR. 72 Corticotropin releasing factor receptor type 1 plays a major role in the stress response via its regulation of endogenous GC and catecholamine production. Our studies of CRH, the major ligand of CRHR1, indicate that in the absence of CRH endogenous GC production decreases and allergen-induced airway inflammation and lung mechanical dysfunction increase dramatically. 73 By extrapolation, genetic or acquired defects in CRHR1 could cause a similar increase in allergen-induced airway inflammation because of insufficient GC production. We postulate that this would result in an increased response to exogenous GC, and that this is the mechanism responsible for the association between CRHR1 polymorphisms and asthmatic GC response. In this regard, our laboratories have recently identified polymorphisms in the CRHR1 that are associated with therapeutic response to GCs. 74 Corticotropin releasing factor receptor type 1 polymorphisms are associated with GC response in asthmatics, we genotyped 12 of these SNPs in adult asthmatics (Adult Study), 311 childhood asthmatics (CAMP), and 336 adult asthmatics (Asthma Clinical Research Network (ACRN)). The primary outcome measure of the association analyses was our continuous FEV 1 phenotype, %DFEV 1 over time in response to inhaled corticosteroids, from baseline to 8 weeks for the Adult Study and CAMP, and baseline to 6 weeks in ACRN. We found individual SNPs or haplotypes that were associated with a significant enhanced response to GC in all three populations. Specifically, SNP rs242941 (minor allele frequency B30%) was associated with positive treatment response in both the Adult Study and CAMP (P ¼ 0.025 and 0.006, respectively). The mean %DFEV 1 for homozygotes for the minor allele vs homozygotes for the major allele was 13.2873.11 vs 5.4971.40 in the Adult Study and 17.8076.77 vs 7.5771.50 for CAMP. Haplotypic analysis revealed one common haplotype (frequency 27%), termed GAT (rs1876828, rs242939, and rs242941), associated with a significantly enhanced response to inhaled corticosteroids in both the Adult Study and CAMP (P ¼ 0.02 and 0.01, respectively). The estimated short-term improvement in FEV1 for those subjects imputed to have the homozygous GAT/GAT haplotype was over twice that for those homozygous for non-GAT haplotypes in the Adult Study (13.7373.80 vs 5.5471.29%), and nearly three times that in CAMP (21.8378.07 vs 7.3571.41%). These findings represent the first genetic association involving GC therapeutic response that has been successfully replicated. It is unknown if any of these variants is functional. 74 ) A systematic analysis of the sequence variation and haplotype structure of the CRHR1 gene will be required to identify Interactions between the glucocorticoid and the b 2 -agonist pathways Dynamic interactions exist between endogenous GC and catecholamines in vivo. In animals, adrenalectomy results in a generalized loss of responsiveness to catecholamines 75, 76 Molecular interactions between the pathways have also gained increasing recognition [77] [78] [79] For instance, both classes of drugs can activate C/EBP-a and the GR. 80, 81 Moreover, both classes of medications combined, even at lower doses, can synchronously activate both transcription factors, resulting in an enhanced antiproliferative effect. 75, [79] [80] [81] [82] b-2 -agonists (particularly long-acting preparations) may affect GR nuclear localization through modulation of GR phosphorylation and, further may prime GR functions within the nucleus by modifying GR or GR-associated protein phosporylation. 83 Glucocorticoids may in turn regulate b 2 AR function by increasing expression and inhibiting b 2 AR downregulation, thereby directly modulating contraction of airway smooth muscle. 81, 84 Pharmacological interactions between GC preparations and b 2 -agonists have been observed, and these interactions are reviewed elsewhere. 79, 85 In clinical trials, the concomitant administration of inhaled corticosteroids and long-acting b 2 -agonists have shown improvements in control of asthma symptoms. 86, 87 Thus, investigating whether interactions between genetic variants in these pathways are able to better predict asthma treatment response is an important goal of this proposal. Practically, all except patients with mild asthma are on both medications (i.e. an inhaled corticosteroid and at least a short acting b-agonist), including most of our trial subjects. Moreover, given the extent of the crosstalk between these therapeutic pathways, it is distinctly possible that candidate genes for the GC pathway may be significantly associated with b 2 -agonist phenotypic outcomes, and vice versa. Indeed, we have found just such an effect with adenylate cyclase 9 (AC9). We genotyped a nonsynonymous AC9 SNP in CAMP and the minor allele frequency for this SNP was 28%. We noted a significantly enhanced mean bronchodilator response (9.2 vs 7.9%, overall effects by ANOVA, P ¼ 0.006; interaction of response by genotype, P ¼ 0.0015) in association with the presence of any variant allele, but only in those children randomized to the inhaled corticosteroid treatment group. The mechanism of the apparent interaction of AC9 genotype, long-term b 2 -agonist response, and corticosteroids is not clear. To begin to explore this, we sought a model cell system whereby b 2 AR is endogenously expressed but AC9 is not, and overnight incubation with corticosteroids induces classic changes in multiple gene expression. The cell line we found that fits these criteria is the A431 line, derived from a lung adenocarcinoma. Using these as the host cells, the wildtype AC9 was stably transfected using the AC9 cDNA without its endogenous promoter, and a line expressing AC9 at levels comparable to endogenous AC5 was chosen for study. Cells were exposed to vehicle or 10 mg/ml dexamethasone for 12 h, and cAMP accumulation ascertained at baseline and in response to 10 min exposure to 10 mM isoproterenol ( Figure 5 ). We found that dexamethasone had little effect on b 2 AR signaling in the absence of AC9 expression. However, isoproterenol stimulated cAMP levels were significantly greater in AC9 expressing cells treated with dexamethasone compared to untreated. Thus, these results indicate an interaction between corticosteroids and the function of AC9 and b 2 AR signaling, which is consistent with the clinical findings. 88 Owingto this potential interaction, we now screen all of the genes in both the b-agonist and the steroid pathways for potential associations with both b-agonist related bronchodilator response and lung function changes related to inhaled corticosteroids.
Overview of pharmacogenetics of asthma treatment study design
Introduction and rationale Although we have had reasonable success in our candidate gene approach to the identification of asthma pharmacogenetic genes to date, we have recently altered our approach to that of a more comprehensive screening approach. The advantages of such an approach are outlined in the paragraphs that follow and in (Table 2 ). These changes were predicated by the increasing availability of high-throughput genotyping and novel statistical methodology. Our global approach is outlined in (Figures 6, 7 and 8 ). Utilizing biologic, pathway, and expression array analysis to identify candidate genes, we are selecting variants in these genes to genotype and test for association with therapeutic response in the CAMP population. After high-throughput genotyping, the screening algorithm developed by Lange et al. 89, 90 will be applied using the available pharmacogenetic phenotypes and genetic data in the CAMP population. The screening algorithm will identify the most promising hypotheses to explore with formal hypothesis testing without affecting the significance level of the subsequent testing. 90 The statistical techniques to test the hypotheses generated in the screening stage will include family-based association methods as well as population-based regression strategies at the single SNP and haplotype levels. These techniques will be applied to the CAMP population and genes that indicate association with pharmacogenetic phenotypes will be sequentially explored in a second and third clinical trial population Significant association results in CAMP that are replicated in the other trial populations will be retested utilizing the method of genomic control to exclude the potential effects of population stratification. Genes with confirmed replications are completely resequenced and functionally evaluated to characterize the etiologic basis underlying the association. Upon completion of the association testing and functional work, the findings are being utilized to develop a predictive model of treatment response, which will be tested on multiple population samples to assess its predictive capabilities. Figure 6 Flow chart for our first specific aim. We screen candidate single-nucleotide polymorphisms (SNPs) within candidate genes using a family-based screening approach, which helps to address issues of multiple comparisons and allows ranking based upon power for replication of a pharmacogenetic effect. After family-based screening, we genotype genes with the most power for replication in our population-based replication cohorts. Replicated genes are then resequenced and evaluated functionally. 
Candidate Genes

Pharmacogenetics of asthma treatment asthma response populations
The PHAT research group utilizes phenotypic information and DNA from multiple clinical trial populations. Although varying in demographic characteristics, and duration of follow-up, all of the subjects included in our analyses met strict definitions for asthma diagnosis and were enrolled in protocol-defined clinical trials. All patients or their legal guardians provided both consent for the study protocol and for ancillary genetic testing. Our primary population consists of a 4-year clinical trial of childhood asthmatics enrolled in CAMP. The two inhaled corticosteroid populations currently available for replication include an 8-week clinical trial of adult asthmatics on flunisolide (Adult Steroid Study), and the 6-week run-in period of a group of adult asthmatics on triamcinolone enrolled through the Asthma Clinical Reserch Network of NHLBI (ACRN). There are also two populations available for b 2 -agonist replication analyses, including a study comparing the efficacy of regular vs levalbuterol sponsored by a pharmaceutical company referred to as the adult b 2 -agonist Study, and a compilation of studies assessing short-term b 2 -agonist response as part of the ACRN. Basic information from these trials is shown in (Table 3) .
Primary analysis population. Childhood Asthma Management Program is a multicenter, longitudinal, randomized, double-blinded clinical trial testing the safety and efficacy of inhaled budesonide vs nedocromil vs placebo (prn b agonist). Trial design and methodology have been previously published. 91 The mean duration of follow-up was 4 years. 92 Childhood Asthma Management Program enrolled 1041 children ages 5-12 years with mild-tomoderate chronic asthma over 23 months. 311 were on on b 22 -agonist (albuterol). Entry criteria included asthma symptoms and/or medication use for 6 or more months in the previous year. Among the exclusion criteria were: prednisone bursts more than five times or more than one hospitalization for asthma in the preceding year, prior intubation for asthma, FEV 1 o65% of normal, and other active pulmonary disease. All study participants had asthmatic range airway responsiveness with a provocative concentration of methacholine causing a 20% reduction in FEV 1 (PC 20 ) p12.5 mg/ml. Follow-up visits occurred at 2 months then every 4 months and spirometry was performed twice yearly. We have chosen to use the CAMP study as our primary population for the following reasons: the available phenotypic data are extremely rich and well-documented, the sample size is large enough to explore both GC and b 2 -agonist pathways, and the availability of familial genetic data enables the application of powerful family-based association screening and testing strategies The family-based association screening and testing strategies will generate and test for genetic associations with pharmacogenetic phenotypes without incurring substantial penalty for multiple comparisons or producing false positive associations due to population stratification.
Populations for follow-up corticosteroid analysis. The Adult Steroid Study was a multicenter 8 week clinical trial used to compare the effect of once daily high-dose inhaled flunisolide vs 'standard inhaled corticosteroid therapy'. Patients were randomized in a 4:1 flunisolide vs other therapy ratio and the study subjects ranged in age from 16 to 75 years, with a slight (58%) female preponderance. Inclusion criteria included a history of asthma and documentation within the previous year of at least 12% improvement in FEV 1 with administration of the short acting b 2 -agonist, albuterol. Additionally, all subjects were required to have been using inhaled steroids at specified doses. Exclusion criteria included a history of significant pulmonary disease other than asthma, smoking in excess of 10 pack-years, and recent upper respiratory infection or asthma exacerbations. Subjects were followed by phone contact on a weekly basis, and had follow-up spirometry at 4 and 8 weeks. In total, 470 moderate to severe adult asthmatics (mean FEV 1 72% at enrollment) had an average improvement in prebronchodilator FEV 1 of 7.0% at the end of the trial period. As the change in the FEV 1 in both treatment groups was the same (P ¼ 0.30), we will combine the treatment groups for our analyses. Two of the completed trials conducted by the ACRN, the salmeterol or corticosteroids (SOCS) and salmeterol7in-haled corticosteroids (SLIC) trials, had a common initial 6 week run-in period utilizing four puffs twice daily of triamcinolone before separate randomization to one of these two trials and have already been utilized (Table 3) . Details regarding the entry criteria, run-in period, and randomization have been published with the primary trial results. 93, 94 These individuals had an average improvement in their FEV 1 of 6.8% during the run-in period. The other ACRN steroid trial subjects in Table 3 are currently being plated for use in genotyping.
Populations for follow-up b 2 -agonist analyses. Initial replication for any positive b 2 -agonist association in CAMP will be performed in an adult study of b 2 -agonist. Subjects were over the age of 18 years and had the full range of asthma severity. Subjects were randomized through three different treatment arms and a placebo PRN albuterol arm. The three treatment arms included 0.63 mg of levalbuterol, 1.25 mg of levalbuterol, and 2.25 mg of racemic albuterol and all treatments were delivered by nebulizer three times daily. Subjects had pulmonary function determined during the run-in period at baseline at randomization and at 2, 4, 6, and 8 weeks of treatment. Dose-effect curves to an acute dose of nebulized b 2 -agonist were determined at each time point and pre-and postbronchodilator FEV 1 and AM peak flows are available at each time point. Our primary analytic end point is the bronchodilator response at randomization. However, subsequent analyses using repeated measures could add to the richness of the analyses. We have multiple, richly characterized, asthma clinical trial populations, including a primary pediatric test population and separate replicate adult corticosteroid and b 2 -agonist populations, to evaluate our hypotheses.
Analysis phenotypes
We plan to assess three phenotypes: one continuous and two categorical (Table 4) . We have explored values other than 20% (conventional dosage of inhaled corticosteroids). We have also replicated results using these phenotypes.
Association analysis strategy and statistical methodology A major criticism of genetic association studies has been the failure to provide demonstrable replication of findings. [95] [96] [97] Failure to replicate findings in genetic association studies has been attributed to variations in study design, including differing study populations and definitions of phenotypes. 96, 97 Conversely, the replication of associations in other, distinct, populations with differing clinical characteristics, such as each of our clinical trial populations, supports both the validity and generalizability of these findings. Using recent advances in statistical genetics, we have implemented a three-stage statistical analysis strategy to identify genetic variants in the candidate genes that demonstrate robust and replicated associations with the treatment response phenotypes. The first and second stage consist of a screen and family-based association test (FBAT) strategy using data from the CAMP population. Genes that are identified as positively associated with treatment response phenotypes in the CAMP population will be genotyped and tested in additional clinical trial populations in the third stage. This multistage strategy optimizes our chances of finding robust and replicated genetic associations with the treatment response phenotypes and minimizes the probability that the significant associations are due to problems arising from multiple testing or population stratification. There are many pitfalls to robust genetic association studies including how to pick the candidate genes and their variants, how to reduce genotyping error, how to avoid population stratification, and multiple comparisons, how to have adequate power. A comprehensive assessment of all of these issues is beyond the scope of this review. However, we believe our approach to association is sound and will achieve the desired goal to ultimately achieve robust replicable and generalizable results. Robust pharmacogenetic associations will be explored at the molecular, cellular, and integrative level to establish functional variants and pharmacogenetic mechanisms. Functional methods will involve bioinformatics tools, mRNA profiling, and cellular and animal models of asthma therapeutic responsiveness (Figure 8 ). Perhaps no issue in genetics is as complex as getting the proper functional variants out of a gene that has replicated in several association studies. Linkage disequilibrium can make it very difficult to definitively pinpoint a specific variant that might be causal. The mouse ova model is commonly used to assess physiology in the whole animal. Less frequently used is an animal model for asthma drug treatment response, that is, an asthma mouse model that can be assessed for b-agonist or steroid treatment response. Similarly, mouse models with knock in/knock outs of the gene of interest are available and frequently used for asthma. More challenging is to create mice with alternative genetic constructs that contain the specific genetic variant or haplotype of interest but these are also achievable.
In vitro assays to test the impact of select variants on gene function or expression For variants that are associated with asthma treatment response and located in conserved regions or regions of potential functional interest, we propose to establish their biological significance by demonstrating, on the basis of experimental data, how a given variant could affect protein function or production and thus how an individual possessing such a sequence variant could have altered asthma therapeutic response. The approach for a given mutation will depend largely on the location of the mutation (i.e., protein coding, splicing region, promoter, 5 0 or 3 0 untranslated region, or intron). The first step is to place the mutation in the context of what is already known about the CRHR1 and CRHR2 genes and their proteins. This is possible because the general structure and function of both genes have been well defined. According to the location of the mutation, it should be possible to make an educated guess as to how the mutation alters receptor production (i.e., promoter, splicing region, or untranslated region mutation) or function (ligand binding, Gs coupling). A general algorithm describing our approach is shown in (Figure 9 ). There are four major types of sequence variants to consider in CRHR1 and CRHR2: protein-coding variants affecting protein function; splicing-site variants affecting RNA splicing; intron/UTR/Other variants affecting RNA stability, splicing, or processing; and promoter variants affecting transcription.
Sequence variants in the protein-encoding region. Nonsynonymous protein coding variants are the most obvious and fairly straightforward to test. In addition to their effects on protein synthesis and structure, variants modifying protein-encoding sequence may also alter ligand binding, Gs coupling, and receptor processing.
Sequence variants in the gene promoter region. Given the high sequence variability found in 5 0 flanking sequences of genes, we anticipate that the CRHR1 and Corticotropin releasing factor receptor type 2 (CRHR2) promoters will contain several common polymorphisms. We have previously described polymorphisms in promoter regions with clinically significant effects on gene expression. For ALOX5 and TGFB1, we have defined transcriptional mechanisms that may be responsible for genetic associations and plan to use a similar approach. 98, 99 We have had extensive experience and success with these assays; to save space, we have not included experimental protocols, but refer the reviewer to our recent publications on polymorphisms in promoter regions with clinically significant effects on gene expression.
Sequence variants in other regions. Sequence variants in intron, intron-exon junctions, or 5 0 -, 3 0 -untranslated regions may affect RNA slicing or stability and result in alternative or truncated protein or altered steady-state levels of RNA. These events can be detected using RNA stability assays or real-time RT-PCR with primers that flank the intron. 100 Differences in the intensity or length of amplified bands may indicate abnormalities caused by the polymorphism. These variants may be particularly important in asthma pharmacogenetics and in complex trait genetics generally. This is because regulatory variation tends to be common, evolutionarily conserved and hence easily detectable with moderate sample sizes and with hapmap identified SNP's.
Animal models of corticosteroid response -the CRH pathway
The CRH pathway consists of a family of ligands and receptors and is more complex than was first appreciated. Corticotropin releasing factor receptor type 1 and the homologous receptor, CRHR2, are the two GPCRs that mediate the biological actions of the CRH pathway. The receptors differ significantly in their tissue distributions, Figure 9 Algorithm for establishing the effect of corticotropin releasing factor receptor (CRHR) mutations -mutation location will be the major determinant of our approach for designing assays to test functional significance.
ligand affinities, and physiological actions. 101 The binding of agonist ligands to these receptors causes a conformational change that transduces signals through activated heterotrimeric Gs. Corticotropin releasing factor receptor type 1 and CRHR2 signal mainly through Gs, increasing adenylyl cyclase activity and cAMP levels; however, these receptors may also couple to Go, Gq, and Gi and signal through other pathways that may involve phospholipase C, protein kinase B/Akt, MAPKs, NOS/guanylyl cyclase, and intracellular Ca 2 þ . 102 The two CRHR receptors are encoded by different genes located on different chromosomes. They are 70% homologous at the amino-acid level and have the characteristic structure of GPCRs, which includes a membranespanning region consisting of seven hydrophobic p-helices, an external N-terminal region for ligand binding, and an internal C-terminal region for signaling. Corticotropin releasing factor receptor type 1 has seven known mRNA splice variants and their relative expression varies with tissue type. Some of these splice variants have significant effects on ligand binding and signaling, and it is possible that some of the polymorphisms associated with asthma may affect CRHR1 function by altering RNA splicing. Corticotropin releasing factor receptor type 2 has at least 3 mRNA splice variants that modify exon 1 and the N-terminal region. As with CRHR1, these splice variants may affect ligand binding, and their relative expression depends on tissue type.
Corticotropin releasing factor receptor type 1 is found mainly in the anterior pituitary and other regions of the brain where it regulates the hypothalamus-pituitary-adrenal (HPA) axis and endogenous GC. Corticotropin releasing factor receptor type 1 is a GPCR that is the major receptor for corticotropin-releasing factor (CRH). A diagram of the first portion of the GC pathway is shown in (Figure 10 ), the full pathway may be viewed on the PharmGKB website (http:// www.pharmgkb.org/index.jsp). Corticotropin-releasing factor is best known as the hypothalamic regulator of pituitary adrenocorticotropin (ACTH) secretion, which stimulates adrenal GC synthesis. Corticotropin-releasing factor is a 41-amino-acid peptide produced by the paraventricular nuclei of the hypothalamus and secreted into the hypophysial portal system in response to inflammatory, physiological, and behavioral forms of stress. 103 Corticotropinreleasing factor binds CRHR1 on corticotrophs of the anterior pituitary and stimulates the release of ACTH, which is an essential regulator of GC and catecholamine secretion by the adrenal glands. Mice deficient in CRH or CRHR1 show adrenal gland atrophy and an inability to produce increased GCs in response to stress. 104 Glucocorticoids Figure 10 The CRF pathway. Within the central nervous system, endogenous corticosteroid production begins with the release of corticotropin releasing factor from the hypothalamus. (From PharmGKB -http://www.pharmgkb.org/index.jsp.) production, as modulated by CRH and the HPA axis, may represent one mechanism by which excessive activation of the immune system is restrained. 105 The mechanisms by which CRHR1 variants affect GC response are unknown. The OVA-sensitization and -challenge mouse model will play a prominent role in the experimental tasks of our ongoing research efforts. It is fortunate that the genes we propose to study have been successfully targeted and that KO mice are available for our studies. We initially hypothesize that CRHdeficiency would increase asthma severity by depressing endogenous GC production in response to inflammatory and physiological stress. Furthermore, CRH-deficiency will increase the response to GC therapy, because exogenous GCs will in effect replace the deficient endogenous GCs that are contributing to asthma severity. To test the first postulate, we subjected CRH-KO and WT mice to an OVA protocol and compared the effects of CRH deficiency on airway inflammation and lung function. We found that KO mice have increased airway inflammation and lung mechanical dysfunction and decreased GC levels compared with WT mice. These data support our concept of 'central' anti-inflammatory action of CRH in asthma. These findings have been published. 99 Our data indicate that in the absence of CRH endogenous GC, production decreases and allergen-induced airway inflammation and lung mechanical dysfunction increase dramatically. 73 By extrapolation, genetic or acquired defects in CRHR1 could cause a similar increase in allergen-induced airway inflammation because of insufficient GC production. We postulate that this would result in an increased response to exogenous GC, and that this is the mechanism responsible for the association between CRHR1 polymorphisms and asthmatic GC response.
Summary
We have demonstrated that asthma prevalence is on the rise and that the disease contributes to significant morbidity, mortality, and cost in the USA. Much of this cost is drug related. The response to inhaled corticosteroids and b 2 -agonists, the most common medications for asthma, is highly variable; much of this variation is genetic. Pharmacogenetics may eventually lead to 'individualized' therapy. Asthma pharmacogenetics is making progress, but the number of replicable associations and the percent phenotypic variance explained by these associations for therapy to inhaled corticosteroids and to b 2 -agonists remains low. The identification of additional genetic variation predictive of therapeutic response in both these pathways remains crucial in order to achieve the goal of the development of prognostic tests to predict treatment response.
